Summary
The calcium antagonists of the dihydropyridine group, isradipine and nifedipine, were compared in 64 patients with mild to moderate hypertension (diastolic blood pressure 95 to 110mm Hg). A 2-week placebo run-in phase was followed by a double-blind crossover trial comprising two 3-week treatment periods with either calcium antagonist. The (fixed) dosages were isradipine 2.5mg twice daily and nifedipine retard 20mg twice daily. Blood pressure (systolic/diastolic) at baseline was 155/101mm Hg and decreased significantly by 14%/15% on isradipine and by 11%/12% on nifedipine (difference between treatments not significant). The drugs differed significantly with regard to incidence of adverse effects (mostly flushing and headache); the total rates were 16% on isradipine and 36% on nifedipine. At the end of the trial, patients were asked which drug or treatment phase they preferred. Isradipine was preferred by 50% of patients; only 20% preferred nifedipine. Thus, it is concluded that isradipine, administered in an equally effective antihypertensive dosage regimen is superior to nifedipine with regard to the incidence of adverse effects, resulting in greater patient satisfaction with treatment.
Similar content being viewed by others
References
Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, et al. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335: 827–838, 1990
Doyle AE. Comparison of calcium antagonists with other antihypertensive agents. Journal of Hypertension 3(Suppl. 3): S531–S533, 1985
Kirch W, Burger KJ, Weidinger G, Welzel D. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension. Journal of Cardiovascular Pharmacology 15(Suppl. 1): S55–S59, 1989
Lund-Johansen P. The hemodynamics of essential hypertension. In Robertson JIS (Ed.) Handbook of hypertension. Clinical aspects of hypertension, Vol. I, pp. 151–173, Elsevier, Amsterdam, 1983
Man in’t Veld A. Calcium antagonists in hypertension. American Journal of Medicine 86(Suppl. 4A): 6–14, 1989
Mauser M, Voelker W, Ickrath O, Karsch KR. Differences of the myocardial properties of the new dihydropyridine calcium channel blocker isradipine as compared to nifedipine with or without additional beta blockade in patients with coronary artery disease. American Journal of Cardiology 63: 40–44, 1988b
Mauser M, Voelker W, Karsch KR. Isradipin (PN 200-110), ein neuer Dihydropyridin-Kalziumantagonist mit geringeren negativ inotropen Eigenschaften im Vergleich zu Nifedipin. Zeitschrift für Kardiologie 77: 373–377, 1988a
Saltiel E, Ellrodt AG, Monk JP, Langley MS. Felodipine — a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 36: 387–428, 1988
von Zerssen D, Koeller DM, Rey ER. Die Befindlichkeitsskala (B-S) — ein einfaches Instrument zur Objektivierung von Befindlichkeitsstörungen, insbesondere im Rahmen von Längsschnitt-Untersuchungen. Arzneimittel Forschung 20: 915–918, 1970
Welzel D, Burger KJ, Weidinger G. Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine. Journal of Cardiovascular Pharmacology 15(Suppl. 1): S70–S74, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Welzel, D., Burger, K.J. The Calcium Antagonist Isradipine in the Therapy of Hypertension. Drugs 40 (Suppl 2), 60–64 (1990). https://doi.org/10.2165/00003495-199000402-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199000402-00015